Dr. Giorgio Trinchieri is the director of the Cancer and Inflammation Program, the head of the Cancer Immunobiology Section, and an NIH distinguished investigator at the National Cancer Institute, National Institutes of Health.
Dr. Trinchieri has advanced our understanding of the relationship between the innate and adaptive immune systems, and discovered interleukin-12 (IL-12), which helps enhance the immune system’s ability to respond to cancer. This last achievement earned him the 1996 William B. Coley Award for Distinguished Research in Basic and Tumor Immunology, and his main focus now is on interplay between innate inflammation, the body’s bacteria, and cancer. In addition to being a member of CRI’s Scientific Advisory Council, Dr. Trinchieri serves on the both the Postdoctoral Fellowip Review Committee and the CLIP Grant Review Committee.
Our findings raise the possibility that the frequent use of antibiotics during a patient’s lifetime or to treat infections related to cancer and its side-effects may affect the success of anti-cancer therapy.
Let's spread the word about Immunotherapy! Click to share this page with your community.